Document is current
Any future updates will be listed below
-
Authors
Ozcifci, Guzin https://orcid.org/0000-0002-4774-9284
Aydin, Tahacan https://orcid.org/0000-0002-8125-4808
Atli, Zeynep https://orcid.org/0000-0002-2959-0978
Balkan, Ilker Inanc https://orcid.org/0000-0002-8977-5931
Tabak, Fehmi https://orcid.org/0000-0001-8632-2825
Oztas, Mert https://orcid.org/0000-0002-4077-1374
Ozguler, Yesim https://orcid.org/0000-0002-2082-4715
Ugurlu, Serdal https://orcid.org/0000-0002-9561-2282
Hatemi, Gulen https://orcid.org/0000-0002-1952-1135
Melikoglu, Melike https://orcid.org/0000-0003-0253-8368
Fresko, Izzet https://orcid.org/0000-0002-8914-9690
Hamuryudan, Vedat https://orcid.org/0000-0001-6625-1652
Seyahi, Emire https://orcid.org/0000-0003-4965-2918
- License Information
-
More Information
Article History
Received: 21 October 2021
Accepted: 13 November 2021
First Online: 25 November 2021
Declarations
:
: Guzin Ozcifci, Tahacan Aydin, Zeynep Atli, Ilker Inanc Balkan, Mert Oztas, Yesim Ozguler, Melike Melikoglu, Izzet Fresko and Vedat Hamuryudan declare that they have no conflict of interest. Fehmi Tabak, has received honoraria, consulting or speaker fees from GSK, MSD, AbbVie and Gilead. Serdal Ugurlu has received honoraria, consulting or speaker fees from Novartis, Pfizer, Lilly and Celltrion. Gulen Hatemi has received research grant from Celgene, honoraria consulting or speaker fees from AbbVie, Amgen, Celgene, Lilly, Novartis and UCB Pharma. Emire Seyahi has received honoraria, consulting or speaker fees from Novartis, Pfizer, AbbVie and Gilead.
Free to read: This content has been made available to all.
